Abstract:
Abstract
This study examines the pharmacokinetics of Diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID), in patients with rheumatoid arthritis (RA) and its modification in the presence of Helicobacter pylori (H. pylori) infection. The results indicate that RA patients experience a significant prolongation of the drug’s half-life, with this effect becoming more pronounced in those with H. pylori infection. Key pharmacokinetic parameters, including elimination constant (Kei), dmg clearance (Cl), and half-life (Tl/2), show noticeable alterations in these patients, leading to slower drug metabolism and clearance. This prolongation increases the risk of side effects, particularly from the gastrointestinal system. Two strategies for minimizing side effects arc suggested: reducing the NSAID dosage or extending dosing intervals, alongside the use of gastroprotcctive agents. In conclusion, RA patients, especially those with comorbid H. pylori infection, require tailored therapeutic regimens to balance efficacy with safety and reduce the likelihood of adverse drug reactions.
